NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

March 13, 2024

First-line niraparib maintenance was not associated with worsened health-related quality of life outcomes vs placebo in advanced ovarian cancer.

February 26, 2024

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

February 15, 2024

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

February 14, 2024

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

February 09, 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

February 08, 2024

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

January 19, 2024

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

January 15, 2024

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

January 15, 2024

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.

January 15, 2024

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.

January 12, 2024

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

January 08, 2024

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.

January 03, 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

December 27, 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

December 27, 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

December 20, 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

December 20, 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

December 18, 2023

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

December 15, 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

December 15, 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.